Home Teva: New Generic Launches Will Benefit Earnings
 

Keywords :   


Teva: New Generic Launches Will Benefit Earnings

2015-01-07 20:18:26| Biotech - Topix.net

Recently, Teva has been authorized by the US Food Drug and Administration to introduce the generic counterpart of Diovan "Valsartan" tablets in the US market. The anticipated elevation in earnings is calculated to be $29 million.

Tags: benefit generic earnings launches

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
More »